RANI
HEALTHCARERani Therapeutics Holdings Inc
What's Moving RANI Today?
No stock-specific AI insight has been generated for RANI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.76
Fundamentals
Trading
RANI News
20 articles- Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·May 26, 2026
- Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionYahoo Finance·May 15, 2026
- Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceYahoo Finance·May 12, 2026
- This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearYahoo Finance·May 8, 2026
- Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyYahoo Finance·Apr 9, 2026
- Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In GrowthYahoo Finance·Mar 28, 2026
- Rani Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateYahoo Finance·Mar 26, 2026
- Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationGlobeNewswire Inc.·Mar 25, 2026
- Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerYahoo Finance·Jan 28, 2026
- Largest borrow rate increases among liquid namesYahoo Finance·Jan 24, 2026
- Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%Yahoo Finance·Jan 23, 2026
- Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGenYahoo Finance·Jan 8, 2026
- Rani Therapeutics to Participate in the Evercore Healthcare ConferenceYahoo Finance·Nov 24, 2025
- RANI: Third Quarter ResultsYahoo Finance·Nov 10, 2025
- Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate UpdateYahoo Finance·Nov 6, 2025
- Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025Yahoo Finance·Oct 30, 2025
- H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill PotentialYahoo Finance·Oct 26, 2025
- Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of DirectorsYahoo Finance·Oct 23, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.76
Fundamentals
Trading
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings Inc. is a pioneering biotechnology company that is revolutionizing the delivery of injectable therapies through its proprietary RaniPill™ technology, enabling oral administration of biologics. This innovative platform addresses critical patient adherence issues and caters to the increasing demand for non-invasive treatment options. With a diverse and promising pipeline targeting various therapeutic areas, Rani Therapeutics is poised to redefine drug delivery methodologies. The company's strong emphasis on research and development, combined with strategic partnerships, positions it for substantial growth and meaningful advancements in the pharmaceutical industry.